Impact of C-reactive protein levels on lipoprotein(a)-associated aortic stenosis incidence and progression.
C-reactive protein
Calcific aortic valve stenosis
Lipoprotein(a)
Journal
European heart journal open
ISSN: 2752-4191
Titre abrégé: Eur Heart J Open
Pays: England
ID NLM: 9918282081406676
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
14
12
2022
revised:
14
02
2023
accepted:
22
03
2023
medline:
20
4
2023
pubmed:
20
4
2023
entrez:
20
04
2023
Statut:
epublish
Résumé
Elevated lipoprotein(a) [Lp(a)] levels are associated with the risk of coronary artery disease (CAD) and calcific aortic valve stenosis (CAVS). Observational studies revealed that Lp(a) and C-reactive protein (CRP) levels, a biomarker of systemic inflammation, may jointly predict CAD risk. Whether Lp(a) and CRP levels also jointly predict CAVS incidence and progression is unknown. We investigated the association of Lp(a) with CAVS according to CRP levels in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk study ( Lp(a) predicts the incidence and possibly progression of CAVS regardless of plasma CRP levels. Lowering Lp(a) levels may warrant further investigation in the prevention and treatment of CAVS, regardless of systemic inflammation.
Identifiants
pubmed: 37077580
doi: 10.1093/ehjopen/oead032
pii: oead032
pmc: PMC10108885
doi:
Types de publication
Journal Article
Langues
eng
Pagination
oead032Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
JAMA Cardiol. 2018 Dec 1;3(12):1212-1217
pubmed: 30476957
J Am Coll Cardiol. 2015 Aug 4;66(5):561-77
pubmed: 26227196
Cleve Clin J Med. 2003 Jul;70(7):634-40
pubmed: 12882386
Eur Heart J. 2003 Jul;24(13):1231-43
pubmed: 12831818
JAMA Cardiol. 2019 Jul 1;4(7):620-627
pubmed: 31141105
Int J Epidemiol. 2014 Aug;43(4):1063-72
pubmed: 23771720
Am J Med. 2008 Oct;121(10 Suppl 1):S15-20
pubmed: 18926165
Am Heart J. 2011 Jun;161(6):1133-9
pubmed: 21641360
Atherosclerosis. 2022 Aug;354:15-22
pubmed: 35803063
J Am Coll Cardiol. 2007 Nov 13;50(20):1992-8
pubmed: 17996566
N Engl J Med. 2009 Dec 24;361(26):2518-28
pubmed: 20032323
JAMA Cardiol. 2020 Oct 1;5(10):1136-1143
pubmed: 32639518
Arterioscler Thromb Vasc Biol. 2012 Dec;32(12):3058-65
pubmed: 23065826
Circulation. 2016 Aug 23;134(8):611-24
pubmed: 27496857
Am Heart J. 2008 Oct;156(4):713-8
pubmed: 18926152
N Engl J Med. 2005 Jun 9;352(23):2389-97
pubmed: 15944423
Open Heart. 2020 Oct;7(2):
pubmed: 33051334
Circ Cardiovasc Genet. 2014 Jun;7(3):304-10
pubmed: 24704946
J Am Coll Cardiol. 2014 Feb 11;63(5):470-7
pubmed: 24161338
J Am Coll Cardiol. 2019 May 7;73(17):2150-2162
pubmed: 31047003
J Lipid Res. 2013 Oct;54(10):2815-30
pubmed: 23828779
N Engl J Med. 2013 Feb 7;368(6):503-12
pubmed: 23388002
J Cardiovasc Risk. 1996 Aug;3(4):373-7
pubmed: 8946268
J Am Coll Cardiol. 2001 Oct;38(4):1078-82
pubmed: 11583885
J Am Coll Cardiol. 2015 Sep 15;66(11):1236-1246
pubmed: 26361154
Circ Res. 2020 May 8;126(10):1346-1359
pubmed: 32160811
Br J Cancer. 1999 Jul;80 Suppl 1:95-103
pubmed: 10466767
Eur Heart J. 2022 Oct 14;43(39):3960-3967
pubmed: 35869873
Metabolites. 2021 Jul 16;11(7):
pubmed: 34357353
CJC Open. 2019 Apr 12;1(3):131-140
pubmed: 32159096
J Am Coll Cardiol. 1997 Mar 1;29(3):630-4
pubmed: 9060903
Lancet. 2010 Jan 9;375(9709):132-40
pubmed: 20031199
J Am Coll Cardiol. 2021 Sep 14;78(11):1083-1094
pubmed: 34503676
J Am Coll Cardiol. 2012 Nov 20;60(21):2218-29
pubmed: 23122790
Circulation. 2010 Jan 19;121(2):306-14
pubmed: 20048204
Am J Cardiol. 2006 Jan 1;97(1):90-3
pubmed: 16377290
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
Circ Cardiovasc Imaging. 2022 Jan;15(1):e013165
pubmed: 34983195
J Heart Valve Dis. 2011 Nov;20(6):639-49
pubmed: 22655494
Pak J Med Sci. 2013 Nov;29(6):1425-9
pubmed: 24550967
J Am Coll Cardiol. 2011 Apr 12;57(15):1611-21
pubmed: 21474042
J Am Coll Cardiol. 2012 Jul 17;60(3):216-23
pubmed: 22789885
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021
pubmed: 33309175